文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺SBRT联合实时运动监测的多中心二期试验:患者报告生活质量分析

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
PubMed 文献 · Pract Radiat Oncol · 2017-08-16

该多中心二期试验纳入66例低中危前列腺癌患者,采用5次7.4 Gy共37 Gy的SBRT并电磁传感器实时监测前列腺运动。中位随访36个月无生化复发,无3级泌尿或肠道毒性,泌尿和肠道生活质量在6-12个月内短暂下降后恢复基线,基线生活质量是持续肠道和性功能的最强预测因子。

要点

  • 5次7.4 Gy共37 Gy的SBRT联合实时运动监测,中位随访36个月无生化复发。
  • 泌尿困扰和肠道生活质量在6-12个月内短暂下降后恢复基线。

核心结论

  • 在多中心二期试验中,使用持续实时评估前列腺运动的前列腺SBRT获得良好的中期肿瘤控制,治疗相关副作用轻微且符合预期。

研究设计与样本

  • 2011年至2013年,5个中心共纳入66例男性患者的前列腺癌SBRT二期试验。
  • SBRT方案为5次7.4 Gy,总剂量37 Gy,使用常规直线加速器,并采用电磁传感器进行运动管理。
  • 通过扩展前列腺癌指数综合26问卷评估健康相关生活质量,按CTCAE 4.0版收集急性和晚期毒性,采用线性混合模型评估生活质量随时间的变化。

主要发现

  • 中位随访36个月,所有患者均为低危或中危疾病,生化复发为0例。
  • 急性和晚期2级及以上肠道毒性发生率分别为4%和5%。
  • 泌尿困扰和肠道生活质量在SBRT后前6至12个月短暂下降,随后恢复至基线。
  • 基线勃起功能良好的男性,性生活质量在前6个月下降,此后趋于稳定;线性混合模型显示基线生活质量是持续肠道和性生活质量的最强预测因子。

临床怎么用

  • 对于低中危前列腺癌患者,可考虑采用5次7.4 Gy共37 Gy的SBRT方案,并联合电磁传感器实时监测前列腺运动。
  • 治疗前应评估基线泌尿、肠道和性生活质量,因其为治疗后持续生活质量的最强预测因子。
  • 应向患者告知泌尿和肠道生活质量可能在治疗后6至12个月内短暂下降,但多可恢复至基线。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of stereotactic body radiation therapy (SBRT) for prostate cancer has been reported predominantly from single institutional studies, although concerns for broader adoption exist. METHODS AND MATERIALS: From 2011 through 2013, 66 men were accrued to a phase 2 trial at 5 centers. SBRT consisted of 5 fractions of 7.4 Gy to a total dose of 37 Gy using conventional linear accelerators. Electromagnetic transponders were used for motion management. Health-related quality of life (HRQOL) was evaluated via the Expanded Prostate Cancer Index Composite 26 questionnaire. Acute and late toxicities were collected according to Common Terminology Criteria for Adverse Events, version 4.0. Linear mixed modeling was performed to assess changes in HRQOL over time. RESULTS: Median follow-up was 36 months. All men had low- or intermediate-risk disease. There have been 0 biochemical recurrences. No grade 3 urinary or bowel toxicity was reported. Twenty-three percent of patients had acute grade 2 urinary toxicity, with 9% late grade 2 urinary toxicity. Four percent and 5% experienced acute or late grade 2+ bowel toxicity, respectively. Urinary bother and bowel HRQOL transiently decreased during the first 6 to 12 months post-SBRT, and then returned to baseline. In men with good erectile function at baseline, sexual HRQOL declined during the first 6 months and stabilized thereafter. On linear mixed modeling, the strongest predictor of sustained bowel and sexual HRQOL was baseline HRQOL. CONCLUSIONS: In this multi-institutional phase 2 clinical trial using continuous real-time evaluation of prostate motion, prostate SBRT has excellent intermediate-term tumor control with mild and expected treatment-related side effects.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jackson WC, Dess RT, Litzenberg DW, et al. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2017. PMID: 29304991. doi:10.1016/j.prro.2017.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。